Top News
Latest News
PARTNERSHIPS
17 Mar 2026
Why Novo Nordisk Is Putting $2 Billion Into a PillREGULATORY
12 Mar 2026
Medicare's GLP-1 Bridge: Who Gets In?INNOVATION
6 Mar 2026
Altimmune's Liver Drug Moves Closer to the Finish LineTECHNOLOGY
4 Mar 2026
AI Maps Brown Fat Genes for Next-Gen Weight Drugs
From Code to Clinic: AI Biotech Grows Up
INSIGHTS
2 Mar 2026
AI drug developers face mounting pressure to turn machine learning breakthroughs into real clinical results
PARTNERSHIPS
17 Mar 2026
Why Novo Nordisk Is Putting $2 Billion Into a Pill
Novo Nordisk and Vivtex join forces in a $2.1B deal to develop next-generation oral biologics for obesity and diabetes
REGULATORY
12 Mar 2026
Medicare's GLP-1 Bridge: Who Gets In?
Medicare launches a temporary program giving eligible patients early, subsidized access to GLP-1 obesity drugs
INNOVATION
6 Mar 2026
Altimmune's Liver Drug Moves Closer to the Finish Line
Altimmune confirms a 2026 Phase 3 launch for pemvidutide, backed by FDA Breakthrough Therapy status and $340M in capital
TECHNOLOGY
4 Mar 2026
AI Maps Brown Fat Genes for Next-Gen Weight Drugs
AI uncovers fat-burning genes that could inspire a new class of obesity drugs targeting metabolism, not appetite
INSIGHTS
2 Mar 2026
From Code to Clinic: AI Biotech Grows Up
AI drug developers face mounting pressure to turn machine learning breakthroughs into real clinical results
INNOVATION
25 Feb 2026
Can AI Rethink How New Drugs Are Found?
Alliance uses AI and clinical data to target IBD, dermatitis, and MS while cutting R&D risks
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.